# Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

> **NCT05524584** · PHASE2 · RECRUITING · sponsor: **University of California, Irvine** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- Hormone Receptor-positive Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Anastrozole
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT05524584
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05524584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05524584, "Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05524584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*